Corno Antonio F
East Midlands Congenital Heart Centre, University Hospitals of Leicester, Leicester, United Kingdom.
Cardiovascular Research Center, University of Leicester, Leicester, United Kingdom.
Front Pediatr. 2018 Jun 7;6:169. doi: 10.3389/fped.2018.00169. eCollection 2018.
PV implantation is indicated for severe PV regurgitation after surgery for congenital heart defects, but debates accompany the following issues: timing of PV implantation; choice of the approach, percutaneous interventional vs. surgical PV implantation, and choice of the most suitable valve. The presence of symptoms is class I evidence indication for PV implantation. In asymptomatic patients indication is agreed for any of the following criteria: PV regurgitation > 20%, indexed end-diastolic right ventricular volume > 120-150 ml/m BSA, and indexed end-systolic right ventricular volume > 80-90 ml/m BSA. The choice of the approach depends upon the morphology and the size of the right ventricular outflow tract, the morphology and the size of the pulmonary arteries, the presence of residual intra-cardiac defects and the presence of extremely dilated right ventricle. Biological valves are first choice in most of the reported studies. A relatively large size of the biological prosthesis presents the advantage of avoiding a right ventricular outflow tract obstruction, and also of allowing for future percutaneous valve-in-valve implantation. Alternatively, biological valved conduits can be implanted between the right ventricle and pulmonary artery, particularly when a reconstruction of the main pulmonary artery and/or its branches is required. Many progresses extended the implantation of a PV with combined hybrid interventional and surgical approaches. Major efforts have been made to overcome the current limits of percutaneous PV implantation, namely the excessive size of a dilated right ventricular outflow tract and the absence of a cylindrical geometry of the right ventricular outflow tract as a suitable landing for a percutaneous PV implantation. Despite tremendous progress obtained with modern technologies, and the endless fantasy of researchers trying to explore new forms of treatment, it is too early to say that either the interventional or the surgical approach to implant a PV can fit all patients with good long-term results.
对于先天性心脏缺陷手术后出现的严重肺动脉瓣反流,可考虑植入肺动脉瓣,但以下问题仍存在争议:肺动脉瓣植入的时机;植入途径的选择,即经皮介入与外科肺动脉瓣植入,以及最合适瓣膜的选择。症状的出现是肺动脉瓣植入的I类证据指征。对于无症状患者,符合以下任何一项标准即可考虑植入:肺动脉瓣反流>20%,舒张末期右心室容积指数>120 - 150 ml/m²体表面积,收缩末期右心室容积指数>80 - 90 ml/m²体表面积。植入途径的选择取决于右心室流出道的形态和大小、肺动脉的形态和大小、心内残余缺陷的存在以及右心室极度扩张的情况。在大多数已报道的研究中,生物瓣膜是首选。相对较大尺寸的生物假体具有避免右心室流出道梗阻的优点,也便于未来进行经皮瓣中瓣植入。另外,可在右心室和肺动脉之间植入带生物瓣膜的管道,特别是当需要重建主肺动脉和/或其分支时。联合介入与外科的混合方法扩展了肺动脉瓣植入的应用。人们已做出重大努力来克服当前经皮肺动脉瓣植入的局限性,即扩张的右心室流出道尺寸过大以及右心室流出道缺乏适合经皮肺动脉瓣植入的圆柱形结构。尽管现代技术取得了巨大进展,且研究人员不断幻想探索新的治疗形式,但要说介入或外科植入肺动脉瓣的方法能使所有患者都获得良好的长期效果,还为时过早。